Leap Therapeutics (LPTX) Competitors

Leap Therapeutics (NASDAQ:LPTX) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends.

Which has more volatility and risk, LPTX or IOBT?

Leap Therapeutics has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Comparatively, IO Biotech has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500.

Does the media refer more to LPTX or IOBT?

In the previous week, IO Biotech had 4 more articles in the media than Leap Therapeutics. MarketBeat recorded 6 mentions for IO Biotech and 2 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 0.93 beat IO Biotech's score of 0.91 indicating that Leap Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Leap Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IO Biotech	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is LPTX or IOBT more profitable?

IO Biotech's return on equity of -86.56% beat Leap Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Leap Therapeutics	N/A	-116.24%	-93.18%
IO Biotech	N/A	-86.56%	-75.24%

Do institutionals and insiders believe in LPTX or IOBT?

30.5% of Leap Therapeutics shares are held by institutional investors. Comparatively, 54.8% of IO Biotech shares are held by institutional investors. 5.4% of Leap Therapeutics shares are held by insiders. Comparatively, 2.3% of IO Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Do analysts rate LPTX or IOBT?

Leap Therapeutics presently has a consensus price target of $4.92, indicating a potential upside of 1,075.95%. IO Biotech has a consensus price target of $9.33, indicating a potential upside of 862.20%. Given Leap Therapeutics' higher probable upside, equities research analysts plainly believe Leap Therapeutics is more favorable than IO Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Leap Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
IO Biotech	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Which has better valuation & earnings, LPTX or IOBT?

IO Biotech is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Leap Therapeutics	N/A	N/A	-$81.41M	-$1.84	-0.23
IO Biotech	N/A	N/A	-$86.08M	-$1.37	-0.71

Does the MarketBeat Community believe in LPTX or IOBT?

Leap Therapeutics received 269 more outperform votes than IO Biotech when rated by MarketBeat users. However, 92.59% of users gave IO Biotech an outperform vote while only 68.37% of users gave Leap Therapeutics an outperform vote.

Company	Underperform	Outperform
Leap Therapeutics	Outperform Votes 294 68.37%	Underperform Votes 136 31.63%
IO Biotech	Outperform Votes 25 92.59%	Underperform Votes 2 7.41%

Summary

IO Biotech beats Leap Therapeutics on 9 of the 16 factors compared between the two stocks.